Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
Key facts
- Who runs it
- Biotech Pharmaceutical Co., Ltd.
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- 3 Apr 2024
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Nimotuzumab injection
- Placebo
- Trifluridine/tipiracil
- Record updated
- 5 October 2026
- Why it stopped
- Study withdrawn before enrollment of any participant due to a corporate strategic decision. Not related to safety or efficacy concerns.
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age 18-75 years old, gender unlimited
- Histologically or cytologically confirmed diagnosis of colorectal cancer (CRC)
- Metastatic colorectal cancer, disease progression after previous second-line or above standard therapy
- Efficacy of previous line therapy containing an anti-EGFR monoclonal antibody (such as panitumumab or cetuximab, etc.) with complete or partial response, or disease stable; and more than 4 months from last dose of anti-EGFR agent administered before randomization
- MSS/pMMR status detected by IHC or PCR
- RAS and BRAF wild-type status
- ECOG Performance Status 0-1
- Measurable disease according to RECIST criteria v1.1
- Life expectancy of at least 3 months
- Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g/dL; absolute neutrophil count (ANC)≥1.5×10\^9/L; white Blood Cell Count≥3.5×10\^9/L;platelets≥100×10\^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN), patients with liver metastases should be ≤ 5 times the ULN; serum creatinine≤1.5×ULN or estimated creatinine clearance > 60 mL/min
- Women of childbearing age should have a negative result of serum HCG or urine pregnancy tests within 72 hours prior to randomization (Postmenopausal women who have had amenorrhea for at least 12 months are considered sterile and women known to have had tubal ligation are not required to undergo pregnancy tests)
- Good compliance and signed informed consent
Who cannot take part
- Has a serious underlying medical condition that makes it impossible to safely administer the trial treatment. Including but not limited to active infections requiring systemic medication: compensatory heart failure (NYHA grade III and IV), unstable angina, and acute myocardial infarction within 3 months prior to enrollment
- Had other malignancies within the past 5 years or at the same time (exceptions include: cured thyroid cancer, non-melanoma skin cancer, carcinoma in situ of the cervix, stage I ductal carcinoma in situ, stage I endometrial cancer or other solid tumors, and effectively treated lymphoma with no evidence of disease for more than 5 years)
- Known allergy to prescription or any component of the prescription used in this study
- Factors that significantly affect oral drug absorption, such as dysphagia, chronic diarrhea, gastrointestinal obstruction, etc; Uncontrolled Crohn's disease or ulcerative colitis
- With HIV or syphilis infection, or active hepatitis (hepatitis B, hepatitis C)
- Patients who received trifluridine/tipiracil or treated with EGFR monoclonal antibody or EGFR tyrosine kinase inhibitor within four months
- Women who are pregnant or are breastfeeding
- Has brain metastases or any symptoms of brain metastases
- Participated in other clinical trials within 4 weeks
- Other reasons that are not suitable to participate in this study according to the researcher's judgment
About the trial
What the trial wants to find out
This is a randomized, double-blind, placebo-controlled, multicenter study. The main purpose of the study is to evaluate the clinical efficacy and safety of nimotuzumab combined with trifluridine/tipiracil in third-line and beyond for the treatment of metastatic colorectal cancer (mCRC). This study planned to be divided into two parts: Part A and Part B. Part A (safety run-in) with a 3 + 3 study design, which primary endpoint is safety; Part B (main study) with a prospective, randomized, double-blind, placebo-controlled design, which primary endpoint is overall survival (OS).
The 2 groups in the trial
- experimental groupTreatment being tested
Nimotuzumab will be administered weekly (dose of nimotuzumab depends on part A). Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Treatment: Nimotuzumab injection and Trifluridine/tipiracil
- control groupPlacebo, for comparison
Placebo will be administered weekly (dose of placebo depends on part A). Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Treatment: Placebo and Trifluridine/tipiracil
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Double-blind, Placebo-controlled, Multicenter Clinical Study of Nimotuzumab Combined With Trifluridine/Tipiracil in Third-line and Beyond for the Treatment of Metastatic Colorectal Cancer
- Record updated
- 5 October 2026